Taste Got Better, Not Worse

People on these drugs routinely say food tastes wrong — metallic, flat, off. A randomized trial measured taste objectively, took biopsies of participants’ tongues, and scanned their brains while they tasted. Taste recognition improved.^[1] That is not the contradiction it appears to be, and understanding why explains something patients have been describing for years.

What was measured, and how deeply

Thirty women with polycystic ovary syndrome, averaging 33.7 years and a BMI of 36.4, were randomized to weekly semaglutide 1.0 mg or placebo for 16 weeks. The study then measured taste at three independent levels, which is unusual at this sample size.

• Taste recognition, using 16 strips carrying four concentrations of each of the four basic tastes.
• Gene expression in the tongue, from actual biopsies.
• Brain activity, by functional MRI, in response both to pictures of food and to a sweet solution dripped onto the tongue.

Three separate kinds of measurement, pointing the same way. For a 30-person trial that is a lot of converging evidence, and it makes the central finding harder to dismiss than a questionnaire result would be.

Why 'better' and 'unpleasant' are both true

Detecting a taste more accurately is not the same as enjoying it.

That resolves the apparent conflict without dismissing anyone. When someone says food tastes strange on this drug, the plausible reading is not that their perception has dulled — it is that it has changed, possibly by becoming more acute, and the familiar no longer matches what they expect.

The brain findings fit that. Reduced putamen activation to pictures of food is a reduction in reward anticipation — wanting it less on sight. A separate change appeared in response to actually tasting sweetness after a meal. Wanting less and perceiving more are different systems, and they moved differently.

None of which has been measured directly. Nobody has run a trial asking whether food is more or less pleasant on these drugs, which is the question patients are actually raising. What patients themselves say about the experience is in eight things patients said.

The design flaw

The gene expression and imaging findings are far less vulnerable to that, because neither is scored by a human judgment in the room. Their agreement with the taste score is what keeps the overall picture credible.

• Thirty participants, all women, all with polycystic ovary syndrome.
• Sixteen weeks, on semaglutide 1.0 mg — the diabetes dose rather than the 2.4 mg used for weight.
• No measure of enjoyment, palatability, or whether people changed what they ate as a result.

What it is useful for

Mostly for reassurance of a specific kind. Altered taste on these drugs is a real, physically grounded phenomenon — there are measurable changes in the tongue and in the brain, not just an impression. Someone reporting that food is different is describing something with biology behind it.

It also suggests taste changes are unlikely to reflect damage. Differential expression of genes governing taste-bud renewal and neural plasticity is the signature of a system adapting rather than degrading, which is a more comfortable thing to be told than that something has been lost.